Influenza A virus H9 subtype (H9 AIV) (H9 AIV)

The Influenza A virus H9 subtype, primarily represented by the H9N2 lineage, is a group of avian influenza viruses that are globally endemic in poultry and pose a significant threat to public health [CDC, 2023]. Although these viruses typically cause mild respiratory symptoms in birds, they are known for their zoonotic potential, frequently infecting humans who have direct contact with infected poultry [Peiris et al., 2001]. A critical feature of the H9 subtype is its role as a genetic reservoir, providing internal gene segments to other highly pathogenic avian influenza viruses such as H5N1 and H7N9 through reassortment [Li et al., 2020]. The virus relies on its Hemagglutinin (H9) protein for host cell attachment and its Neuraminidase (N2) enzyme for the release of progeny virions from the cell surface [NCBI, 2024]. Therapeutic strategies include the use of neuraminidase inhibitors like oseltamivir and polymerase inhibitors like baloxavir marboxil, though the effectiveness of older M2 ion channel blockers is compromised by widespread resistance [Sun and Liu, 2015]. Monitoring the evolution of this subtype is vital for pandemic preparedness and the development of effective vaccines [WHO, 2024].

Other names

Avian influenza H9H9N2 virusA(H9N2)H9 subtype influenza A virusAvian influenza A(H9)

Drugs targeting the H9 subtype function by inhibiting the neuraminidase enzyme to prevent viral shedding, blocking the M2 ion channel to stop viral uncoating, or inhibiting the cap-dependent endonuclease of the viral polymerase complex to halt RNA synthesis.